• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.

作者信息

Ji Jie, Liu Ting, Xiang Bing, Liu Weiping, He Chuan, Chen Xinchuan, Li Jianjun, Chang Hong, Dai Yang, Dong Tian

机构信息

Department of Hematology, West China Hospital of Sichuan University , Chengdu , China.

出版信息

Leuk Lymphoma. 2014 Dec;55(12):2955-7. doi: 10.3109/10428194.2014.907894. Epub 2014 May 6.

DOI:10.3109/10428194.2014.907894
PMID:24679007
Abstract
摘要

相似文献

1
A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.吉西他滨、左旋门冬酰胺酶、异环磷酰胺、地塞米松和依托泊苷化疗方案用于新诊断的IV期、复发或难治性鼻型结外自然杀伤/T细胞淋巴瘤的研究
Leuk Lymphoma. 2014 Dec;55(12):2955-7. doi: 10.3109/10428194.2014.907894. Epub 2014 May 6.
2
Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.地塞米松、甲氨蝶呤、异环磷酰胺、L-天冬酰胺酶和依托泊苷（SMILE）化疗方案用于晚期、复发或难治性结外自然杀伤（NK）/T细胞淋巴瘤和白血病的I期研究
Cancer Sci. 2008 May;99(5):1016-20. doi: 10.1111/j.1349-7006.2008.00768.x. Epub 2008 Feb 19.
3
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.吉西他滨、聚乙二醇天冬酰胺酶、顺铂和地塞米松（DDGP）联合化疗治疗复发/难治性结外NK/T细胞淋巴瘤的疗效：一项对17例患者的回顾性研究
Ann Hematol. 2014 Nov;93(11):1889-94. doi: 10.1007/s00277-014-2136-7. Epub 2014 Jun 13.
4
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.DDGP 方案与 SMILE 方案治疗初治中高危 NK/T 细胞淋巴瘤的随机对照、多中心、开放标签研究 **解析**：原文是一篇医学研究论文的标题，包含了医学专业术语“Natural Killer/T-Cell Lymphoma”，意思是“自然杀伤/T 细胞淋巴瘤”。译文忠实反映了原文的内容，准确传达了其含义。
Clin Cancer Res. 2016 Nov 1;22(21):5223-5228. doi: 10.1158/1078-0432.CCR-16-0153. Epub 2016 Apr 8.
5
SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.SVILE 方案，即地塞米松、长春碱、异环磷酰胺、培门冬酶和依托泊苷联合方案，用于治疗复发/难治性结外鼻型自然杀伤/T 细胞淋巴瘤。
Leuk Res. 2020 Sep;96:106422. doi: 10.1016/j.leukres.2020.106422. Epub 2020 Jul 16.
6
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.SMILE 方案治疗自然杀伤/T 细胞淋巴瘤的疗效和安全性：亚洲淋巴瘤研究组的分析。
Blood. 2012 Oct 11;120(15):2973-80. doi: 10.1182/blood-2012-05-431460. Epub 2012 Aug 23.
7
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.SMILE 化疗治疗初诊 IV 期、复发或难治性结外鼻型自然杀伤（NK）/T 细胞淋巴瘤的 II 期研究：NK 细胞肿瘤研究组研究。
J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.
8
A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.甲氨蝶呤、依托泊苷、地塞米松和聚乙二醇天冬酰胺酶化疗用于新诊断、复发或难治性鼻型结外自然杀伤/T细胞淋巴瘤的2期研究：中国西北多中心试验
Hematol Oncol. 2017 Dec;35(4):619-629. doi: 10.1002/hon.2325. Epub 2016 Oct 10.
9
The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.用于治疗鼻型结外自然杀伤（NK）/T细胞淋巴瘤的DDGP（顺铂、地塞米松、吉西他滨和聚乙二醇天冬酰胺酶）方案。
Oncotarget. 2016 Sep 6;7(36):58396-58404. doi: 10.18632/oncotarget.11135.
10
Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant.采用地塞米松、甲氨蝶呤、异环磷酰胺、L-天冬酰胺酶和依托泊苷化疗，随后进行自体干细胞移植，成功治疗了伴有严重噬血细胞综合征的鼻型结外自然杀伤/T细胞淋巴瘤。
Leuk Lymphoma. 2010 Apr;51(4):720-3. doi: 10.3109/10428191003682742.

引用本文的文献

1
Integration of anti-PD-1 antibody into chemotherapeutic regimens improved the outcome of aggressive NK cell leukemia: a single-center retrospective real-world analysis.将抗程序性死亡蛋白1（PD-1）抗体纳入化疗方案可改善侵袭性自然杀伤细胞白血病的治疗结果：一项单中心回顾性真实世界分析。
Front Immunol. 2025 Apr 14;16:1576904. doi: 10.3389/fimmu.2025.1576904. eCollection 2025.
2
Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.两种基于 L-天冬酰胺酶的化疗方案治疗初诊鼻腔型结外 NK/T 细胞淋巴瘤的临床疗效比较。
Cancer Med. 2023 Apr;12(8):9458-9470. doi: 10.1002/cam4.5708. Epub 2023 Mar 31.
3
A controlling nutritional status score is an independent predictor for patients with newly diagnosed nasal-type extranodal NK/T-cell lymphoma based on asparaginase-containing regimens.
基于含门冬酰胺酶方案，控制营养状态评分是新发鼻型结外 NK/T 细胞淋巴瘤患者的独立预测因子。
Cancer Med. 2023 Apr;12(8):9439-9448. doi: 10.1002/cam4.5706. Epub 2023 Mar 3.
4
Treatment of extranodal NK/T-cell lymphoma: From past to future.结外 NK/T 细胞淋巴瘤的治疗：从过去到未来。
Front Immunol. 2023 Feb 7;14:1088685. doi: 10.3389/fimmu.2023.1088685. eCollection 2023.
5
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG.基于一线非蒽环类药物的化疗方案治疗结外鼻型 NK/T 细胞淋巴瘤：一项来自 CLCG 的回顾性分析。
Blood Adv. 2020 Jul 14;4(13):3141-3153. doi: 10.1182/bloodadvances.2020001852.
6
[Efficacy of GLIDE chemotherapy for patients with newly diagnosed advanced-stage or relapsed/refractory extranodal natural killer cell lymphoma].[GLIDE化疗方案对新诊断的晚期或复发/难治性结外自然杀伤细胞淋巴瘤患者的疗效]
Zhonghua Xue Ye Xue Za Zhi. 2016 Sep 14;37(9):751-755. doi: 10.3760/cma.j.issn.0253-2727.2016.09.005.
7
Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma.挽救性化疗后的巩固治疗可改善复发结外自然杀伤/T细胞淋巴瘤患者的预后。
Sci Rep. 2016 Apr 4;6:23996. doi: 10.1038/srep23996.